Polymer blend-bioceramic composite implantable medical devices

• US 7,842,737 B2
• Filed: 09/29/2006
• Issued: 11/30/2010
• Est. Priority Date: 09/29/2006
• Status: Expired due to Fees

• Current Assignee: Advanced Cardiovascular Systems Incorporated (Abbott Laboratories)
• Original Assignee: Abbott Cardiovascular Systems Incorporated (Abbott Laboratories)
• Inventors: Wang, Yunbing, Gale, David C.
• Primary Examiner(s): Yoon; Tae H
• Application Number:
  US11/529,996
• Publication Number:
  US 20080081063A1
• Time in Patent Office: 1,523 Days
• Field of Search: 523/113, 523/114, 524/414, 525/88, 525/931, 623/1.49
• US Class Current: 523/113
• CPC Class Codes: A61L 31/128 containing other specific inorganic fillers not covered by A61L31/126 or A61L31/127
• CPC Class Codes: A61L 31/148 Materials at least partially resorbable by the body
• CPC Class Codes: C08L 67/04 Polyesters derived from hydroxycarboxylic acids, e.g. lactones C08L67/06 takes precedence
• CPC Class Codes: Y10S 525/931 Blend of stated incompatibility

Abstract

Methods and devices relating to polymer blend/bioceramic composite implantable medical devices are disclosed.

Claims

1. An implantable medical device comprising a structural element, the structural element including:

a continuous phase comprising a matrix polymer; and

a discrete phase within the continuous phase, the discrete phase comprising a modifier polymer having discrete phase segments, the discrete phase segments being immiscible with the matrix polymer, the modifier polymer further comprising anchor segments that are miscible with the matrix polymer, the anchor segments at least partially phase separate from the discrete phase into the continuous phase,

wherein the matrix polymer and the modifier polymer are biodegradable polymers,

wherein a plurality of bioceramic particles are dispersed within the continuous and/or the discrete phase, and

wherein the structural element is 5-20 wt% of a modifier polymer and about 75-95 wt% of matrix polymer.

2. The device of claim 1, wherein the implantable medical device is a stent.

3. The device of claim 1, wherein a majority of the continuous phase comprises the matrix polymer.

4. The device of claim 1, wherein the discrete phase segments have a T_g below body temperature.

5. The device of claim 1, wherein the discrete phase segments comprise an elastomer.

6. The device of claim 1, wherein the matrix polymer is selected from the group consisting of poly(L-lactide), poly(L-lactide-co-glycolide), and a combination thereof.

7. The device of claim 1, wherein the discrete phase segments comprise monomers selected from the group consisting of caprolactone, trimethylene carbonate, and glycolide.

8. The device of claim 1, wherein the modifier polymer is selected from the group consisting of poly(glycolide-co-ε

-caprolactone)-b-poly(L-lactide), poly(L-lactide)-b-poly(glycolide-co-ε

-caprolactone), poly(glycolide-co-ε

-caprolactone)-b-poly(L-lactide-co-glycolide), poly(L-lactide-co-glycolide)-b-poly(glycolide-co-ε

-caprolactone), and a combination thereof

9. The device of claim 1, wherein the bioceramic particles are nanoparticles.

10. The device of claim 1, wherein the particles are uniformly or substantially uniformly dispersed within one or both of the phases.

11. The device of claim 10, wherein the bioceramic particles are biodegradable.

12. The device of claim 10, wherein the degradation products of the bioceramic particles are capable of modifying a degradation rate of the matrix polymer and/or the modifier polymer during use of the device.

13. The device of claim 10, wherein the degradation products of the particles are either basic or acidic.

14. The device of claim 1, wherein the bioceramic particles are selected from a group consisting of calcium and phosphate compounds.

15. The device of claim 1, wherein a surface of the bioceramic particles comprises an adhesion promoter, the adhesion promoter enhancing bonding between the matrix and/or the modifier polymer and the bioceramic particles.

16. The device of claim 15, wherein the adhesion promoter comprises coupling agents.

17. The device of claim 15, wherein the adhesion promoter is selected from a group consisting of 3-aminopropyltrimethoxysilane, 3-aminopropyltriethoxysilane and aminopropylmethyldiethoxy silane.

18. The device of claim 1, wherein the particles increase the toughness of the structural element of the device at physiological conditions.

19. The device of claim 1, wherein the particles increase the modulus of the structural element of the device at physiological conditions.

20. The device of claim 1, wherein the discrete phase further comprises a copolymer comprising discrete phase segments with no anchor segments.

21. The device of claim 1, wherein the structural element has between 0.1 and 1 wt% bioceramic particles.